All In Biotech

Drug Trial Radar · NCT02829827

A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

An Open-label Adaptive Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Radiprodil in Subjects With Drug-resistant Infantile Spasms

Last checked: Nov 19, 2026Latest source record: Sep 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

3

Actual

Start

Dec 4, 2017

Primary completion

Oct 2, 2018

Study completion Oct 2, 2018

Sponsor

Lead sponsor
UCB Biopharma S.P.R.L.UCB
Sponsor type
Industry
First posted
Jul 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 months, up to 14 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and tolerability, the pharmacokinetics and the efficacy of radiprodil in abolishing clinical spasms in subjects with drug-resistant infantile spasms

Conditions

  • Infantile Spasms (IS)

Interventions

  • RadiprodilDrug

    Radiprodil at individualized doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with clinical response on Day 14 of treatment with the maintenance dose of radiprodilTime frame: Day 14, counting from the first day of radiprodil at maintenance dose
  2. Estimates of exposure generated from a population-Pharmacokinetic modellingTime frame: Samples will be taken at baseline (time during Day -14 to -1 prior to dosing) and 3, 4, 5 & 12hr after the 1st dose on Day 1 of radiprodil low, mid & high dose. Blood samples will be taken at same timepoints after 1st dose on Day 2 of radiprodil low dose
  3. Percentage of subjects with electro-clinical response on Day 14 of treatment with the maintenance dose of radiprodilTime frame: Day 14, counting from the first day of radiprodil at maintenance dose
  4. Incidence of Adverse Events (AEs) during the studyTime frame: From Baseline (Day -1) to the end of the Post-treatment Period (28 days post last dosing)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ep0078 401

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.